News and Announcements
Actinogen Medical Ltd (ASX: ACW) Alzheimer’s Treatment Receives Final Market Patent
- Published October 25, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Canadian Intellectual Property Office approved another major patent for Xanamem, Actinogen Medical Limited (ASX: ACW) breakthrough Alzheimer’s treatment
- Xanamem now holds a patent in over 80% of Alzheimer’s market worldwide including Japan, European Union, United Kingdom, China, United States and Australia
Actinogen Medical Limited (ASX: ACW) announced that the Canadian Intellectual Property Office has approved a patent for Xanamem in Canada for a period up to 2031. This means Xanamem now has patents in all major markets in the world including Japan, European Union, United Kingdom, China, United States and Australia. These countries represent more than 80% of Alzheimer’s market worldwide.
Xanamem, which was discovered by Dr Scott Webster and Professor Brian Walker, was developed as a treatment for Alzheimer’s diseases. Scientists believe that increased cortisol levels in the blood lead to the disease. Xanamem aims to reduce the harmful effects of the disease by blocking the production of cortisol.
The hypothesis that increased cortisol levels cause Alzheimer’s disease is supported by the Australian Imaging, Biomarker & Lifestyle Study of Ageing (AIBL) study. The authors agreed that Alzheimer’s diseases could be prevented by lowering the levels of cortisol.
The patent for Xanamem, however, covers not only Alzheimer’s diseases but a wide array of metabolic and neurological diseases. It also includes a patent for Xanamem’s composition. Those in the pharmaceutical industry usually seek patents for compositions and compounds as well as exclusive rights to the concerned drugs and this is the patent awarded to Xanamem.
“The strength of the Xanamem IP we are developing is reaffirmed with the grant of patents in these key countries. Xanamem is now patent protected in more than 80% of the global Alzheimer’s market, signalling the significant value of the Xanamem IP that we hope to commercialise in the future.” Actinogen Medical CEO and Managing Director Dr Bill Ketelbey said.
Actinogen Limited, now known as Ectinogen Medical Limited, specialises in the treatment of mild cognitive impairment and the more serious dementia and Alzheimer’s disease. The company is developing Xanamem, a drug that aims to treat not only Alzheimer’s but also neurodegenerative diseases related to age.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
